Danaher Corporation will add a portfolio of antibodies, reagents, biomarkers, and assays to its life sciences offering through the acquisition of Abcam. According to the firms, Danaher has emerged as victor among “more than 20 potential strategic acquirers” in the race to buy Abcam, paying $24 per share, totalling approximately $5.7 billion. “Our strategy has transformed Abcam to become a scale innovator and important catalyst in the global life science community,” said Abcam CEO Alan Hirzel. “Danaher shares our passion…